NOVOCOL PHARMA
LIVE

Serial Number

88692164

Owner

SEPTODONT HOLDING SAS

Attorney

Jason J. Mazur

Filing Date

Nov 14, 2019

Add to watchlist:

No watchlists yet
View on USPTO

NOVOCOL PHARMA Trademark

Serial Number: 88692164

NOVOCOL PHARMA is a trademark filed by SEPTODONT HOLDING SAS on November 14, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

SEPTODONT HOLDING SAS (9 trademarks)

58, RUE DU PONT DE CRETEIL
SAINT-MAUR-DES FOSSES CEDEX 941 , FR

Entity Type: 34

Trademark Details

Filing Date

November 14, 2019

Registration Date

Not Registered

Published for Opposition

February 20, 2024

Goods & Services

(Based on 44(e)) Contract manufacturing of clinical batches of pharmaceuticals; (Based on Use) consulting services relating to pharmaceutical manufacturing and batch biological treatment batches; none of the foregoing for the treatment of cancer or oncological diseases and disorders

(Based on 44(e)) Pharmaceutical products, namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations for treatment of dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders

(Based on 44(e)) Business consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies, method development, formal stability, registration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders

(Based on 44(e)) Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; (Based on Intent to Use) consulting services relating to pharmaceuticals in the field of regulatory compliance, namely, regulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders

(Based on 44(e)) Drug delivery systems, consisting of needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders

(Based on 44(e)) Pharmaceutical drug development services, namely, the formulation of new dosage forms and the reformulation of existing drug products; (Based on Intent to Use) consulting services relating to clinical testing, inspection, or research of pharmaceuticals; consulting services relating to conducting pharmaceutical stability studies and formal stability studies; consulting services relating to the development of chemical production methods; consulting services relating to registration batch research and commercial pharmaceutical products development; none of the foregoing for the treatment of cancer or oncological diseases and disorders

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 4, 2025 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Jan 4, 2025 SUPC
SOU EXTENSION 1 GRANTED
Jan 4, 2025 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 3, 2025 AITU
USE AMENDMENT FILED
Oct 16, 2024 IUAF
SOU EXTENSION 1 FILED
Oct 16, 2024 EXT1
TEAS STATEMENT OF USE RECEIVED
Oct 16, 2024 EISU
SOU TEAS EXTENSION RECEIVED
Oct 16, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 16, 2024 NOAM
CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Mar 12, 2024 CHPB
ASSIGNED TO PETITION STAFF
Mar 11, 2024 APET
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 20, 2024 PUBO
TEAS POST PUBLICATION AMENDMENT RECEIVED
Feb 8, 2024 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 1, 2024 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 1, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 31, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 17, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 16, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 16, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 16, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 16, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 23, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 23, 2023 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 21, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 2, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 2, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 2, 2023 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 27, 2023 RCCK
ASSIGNED TO EXAMINER
Sep 18, 2023 DOCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 2, 2023 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 8, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 8, 2023 GNSL
SUSPENSION LETTER WRITTEN
Feb 8, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 8, 2023 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 8, 2023 CHAN
ASSIGNED TO LIE
Feb 8, 2023 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Feb 1, 2023 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 8, 2022 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 8, 2022 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 8, 2022 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 18, 2022 RCCK
ASSIGNED TO EXAMINER
Mar 9, 2022 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 1, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 1, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 1, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 1, 2022 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 10, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 10, 2022 GNSL
SUSPENSION LETTER WRITTEN
Jan 10, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 10, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 10, 2022 CRFA
ASSIGNED TO LIE
Jan 3, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 28, 2021 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jul 1, 2021 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jul 1, 2021 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 1, 2021 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 30, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 30, 2020 GNSL
SUSPENSION LETTER WRITTEN
Dec 30, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 29, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 29, 2020 CRFA
ASSIGNED TO LIE
Dec 28, 2020 ALIE
ASSIGNED TO LIE
Dec 16, 2020 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 21, 2020 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 18, 2020 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 18, 2020 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 18, 2020 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 18, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 18, 2020 GNSL
SUSPENSION LETTER WRITTEN
Mar 18, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Feb 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Feb 20, 2020 CNRT
ASSIGNED TO EXAMINER
Feb 19, 2020 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 21, 2019 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 20, 2019 NWOS
NEW APPLICATION ENTERED
Nov 18, 2019 NWAP